NGL Fine Chem Ltd
Established in 1981, NGL Fine-Chem Limited manufactures human and veterinary bulk drugs, intermediates, and formulations. It primarily deals in animal healthcare products such as antiprotozoal, anthelmintics, and growth promoters [1]
- Market Cap ₹ 1,436 Cr.
- Current Price ₹ 2,324
- High / Low ₹ 2,824 / 1,711
- Stock P/E 37.3
- Book Value ₹ 425
- Dividend Yield 0.08 %
- ROCE 18.8 %
- ROE 15.8 %
- Face Value ₹ 5.00
Pros
Cons
- Earnings include an other income of Rs.15.9 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
56 | 79 | 88 | 96 | 100 | 114 | 153 | 152 | 258 | 319 | 275 | 329 | |
48 | 68 | 73 | 74 | 74 | 92 | 121 | 129 | 181 | 253 | 246 | 285 | |
Operating Profit | 8 | 11 | 15 | 22 | 25 | 22 | 32 | 23 | 77 | 66 | 29 | 44 |
OPM % | 14% | 14% | 17% | 23% | 26% | 19% | 21% | 15% | 30% | 21% | 10% | 13% |
0 | -1 | 2 | 0 | 1 | 3 | 4 | 1 | 9 | 13 | 8 | 16 | |
Interest | 1 | 2 | 2 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 2 | 1 |
Depreciation | 2 | 2 | 3 | 3 | 3 | 5 | 6 | 7 | 7 | 8 | 8 | 8 |
Profit before tax | 4 | 7 | 13 | 18 | 23 | 18 | 28 | 14 | 76 | 69 | 27 | 51 |
Tax % | 35% | 32% | 35% | 36% | 35% | 29% | 27% | 26% | 27% | 24% | 24% | 24% |
3 | 5 | 8 | 11 | 15 | 13 | 20 | 11 | 55 | 52 | 20 | 39 | |
EPS in Rs | 4.71 | 7.33 | 13.48 | 18.45 | 24.10 | 20.38 | 32.58 | 17.16 | 89.79 | 84.57 | 32.57 | 62.35 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 10% | 2% | 2% | 5% | 3% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 17% |
3 Years: | 8% |
TTM: | 20% |
Compounded Profit Growth | |
---|---|
10 Years: | 23% |
5 Years: | 14% |
3 Years: | -11% |
TTM: | 91% |
Stock Price CAGR | |
---|---|
10 Years: | 56% |
5 Years: | 34% |
3 Years: | 5% |
1 Year: | 24% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 21% |
3 Years: | 17% |
Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 17 | 21 | 30 | 41 | 56 | 69 | 89 | 98 | 152 | 203 | 222 | 260 |
13 | 17 | 13 | 14 | 23 | 27 | 27 | 28 | 16 | 30 | 32 | 32 | |
14 | 15 | 21 | 19 | 20 | 31 | 23 | 26 | 34 | 41 | 30 | 58 | |
Total Liabilities | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 | 288 | 353 |
18 | 19 | 17 | 24 | 25 | 56 | 61 | 61 | 58 | 59 | 59 | 60 | |
CWIP | 0 | 0 | 1 | 2 | 16 | 3 | 0 | 0 | 1 | 6 | 26 | 46 |
Investments | 0 | 0 | 2 | 3 | 6 | 6 | 9 | 14 | 33 | 32 | 43 | 57 |
30 | 37 | 46 | 49 | 55 | 63 | 73 | 80 | 115 | 180 | 159 | 190 | |
Total Assets | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 | 288 | 353 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0 | -0 | 8 | 8 | 10 | 22 | 9 | 20 | 27 | 13 | 32 | 11 | |
-3 | -4 | -3 | -10 | -10 | -21 | -10 | -19 | -24 | -13 | -24 | -17 | |
4 | 3 | -4 | 2 | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | |
Net Cash Flow | 1 | -1 | 1 | 0 | -0 | 1 | -1 | -0 | 2 | -1 | 7 | -7 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 100 | 110 | 107 | 123 | 110 | 89 | 79 | 63 | 53 | 74 | 86 | 92 |
Inventory Days | 126 | 77 | 106 | 90 | 114 | 134 | 106 | 154 | 132 | 133 | 69 | 101 |
Days Payable | 148 | 105 | 150 | 122 | 139 | 187 | 92 | 114 | 94 | 84 | 59 | 112 |
Cash Conversion Cycle | 78 | 82 | 63 | 91 | 85 | 35 | 93 | 103 | 91 | 124 | 97 | 81 |
Working Capital Days | 88 | 88 | 77 | 96 | 85 | 54 | 107 | 98 | 78 | 116 | 104 | 166 |
ROCE % | 19% | 24% | 29% | 37% | 34% | 22% | 28% | 15% | 52% | 35% | 12% |
Documents
Announcements
- Intimation Pursuant To Reg. 30 Of SEBI (LODR) Regulations, 2015. 1d
- Closure of Trading Window 27 Jun
- Announcement Under Regulation 30 (LODR), 2015 18 Jun
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 6 Jun
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1 Jun - The Company participated in the Investors Conference Call on Tuesday, 28th May, 2024, enclosed herewith please find transcript of earnings conference call on audited Financial …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT REC
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
Dec 2019TranscriptPPT
Product Portfolio FY24
Presently, Veterinary APIs are the main product of the company which account for 89% of its revenues, followed by Veterinary Formulations (5%), Human APIs (3%), and Intermediates (3%).[1] The company has 26 APIs (24 Veterinary APIs, 2 Human APIs), 4 Intermediates and 10 finished dosage forms.[2]